AstraZeneca Plc

AstraZeneca Plc: Reuters Pfizer Inc, which in May abandoned its $118 billion bid for AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals, according to Euro News. Under UK takeover rules, AstraZeneca can attempt to re-engage with Pfizer in August, and Pfizer can make another run at AstraZeneca in November and By Ransdell Pierson The largest U.S. drugmaker reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines. But overall sales fell on competition with newer rival drugs and cheaper generics, trends that have quickened Pfizers efforts to buy companies and drugs that can fortify its medicine chest. (news.financializer.com). As reported in the news.